RemeGen (REGMF) Stock Price, News & Analysis

Company Overview

RemeGen Co., Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.

RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma. Beyond RC48, the company is developing additional ADCs against targets such as EGFR and HER3, as well as bispecific antibodies designed to engage both tumor antigens and the patient’s immune system. RemeGen’s pipeline programs include novel immuno-oncology candidates that are currently undergoing clinical evaluation in China, with investigational studies planned or underway in multiple tumor types.

While RemeGen is headquartered in Shanghai, it has established strategic partnerships to support global development and commercialization. The company has outlicensed rights to its lead ADC outside of Greater China and collaborates with international organizations on late-stage clinical trials. RemeGen’s management team comprises industry veterans with expertise in biologics research, regulatory affairs and commercial operations. Together, they aim to expand patient access to next-generation antibody therapies in both domestic and overseas markets.

Key Stats

• Today's Range: $10.95 to $10.95
• 50-Day Range: $10.00 to $10.95
• 52-Week Range: $9.81 to $15.91
• Volume: N/A
• Average Volume: 1,000 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

REGMF Stock Analysis - Frequently Asked Questions

How have REGMF shares performed this year?

RemeGen's stock was trading at $9.81 on January 1st, 2026. Since then, REGMF stock has increased by 11.6% and is now trading at $10.9491.

How do I buy shares of RemeGen?

Shares of REGMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:REGMF
• CIK: N/A
• Web: www.remegen.com
• Phone: 86-53-56357-3672
• Fax: N/A
• Employees: 3,615
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A